Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 31722-934

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 31722-934). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Drosee28sfoil (Drosee28sfoil)

This appears to be a label of a medical product called "Placebo Drosgirenone and Etiny Estardil Tablts, USP" manufactured by Cyndea Pharma in Spain. The medication is composed of 3 mg Drospirenone and 0.02 mg Ethinyl Estradiol and available only by prescription. The label also contains information about the recommended storage temperature.*

FDA Label Image

Droseeblodclot (Droseeblodclot)

This text provides information about the ranges of blood clot incidents for non-pregnant women and women who are not using combined oral contraceptives (COC). It also includes ranges for COC users, postpartum women (up to 12 weeks), and incidence rates of blood clots per 10,000 Women Years (WY) for each category. The pregnancy data is based on actual pregnancy durations, and the text provides a model rate for blood clot incidents during pregnancy assuming a pregnancy duration of nine months.*

FDA Label Image

Droseechart (Droseechart)

This text provides information about the different birth control methods and their effectiveness rates in preventing pregnancy. The text also presents data on the number of pregnancies per 100 women within a year, ranging from less than 1 to 850 or more. It suggests various birth control options such as implants, injections, intrauterine devices (IUDs), sterilization, contraceptive pills, skin patch, vaginal ring, condoms, diaphragm, spermicide, withdrawal, and avoiding sex during the most fertile days of the monthly cycle.*

FDA Label Image

Droseedaylabel (Droseedaylabel)

This text appears to be a template for Drospirenone and Ethinyl Estradiol Tablets USP, with a space to select the appropriate start day based on a chart provided. The chart has the days of the week arranged horizontally and vertically, with options for which day to start the medication. The purpose of the medication is not stated.*

FDA Label Image

Droseedoseorder (Droseedoseorder)

FDA Label Image

Droseefigure1 (Droseefigure1)

This text appears to be a collection of hazard ratios, rate ratios, and odds ratios from various studies such as FDA-funded study, Danish re-analysis, MEGA study, German case-control, PharMetrics, and GPRD study. The studies include prospective and retrospective cohort studies, case-control studies, and non-fatal idiopathic cases. The numbers 0.1 and 0.2 are also present in the text.*

FDA Label Image

Droseefigure2 (Droseefigure2)

This is a chart outlining the different ranges of blood clot risk for non-pregnant individuals, non-COC users, COC users, individuals postpartum (within 12 weeks). It includes the number of women with a blood clot per 10,000 women years (WY). The pregnancy data is based on the actual duration of pregnancy and rate is 7 to 27 per 10,000 WY based on a model assumption that pregnancy duration is nine months.*

FDA Label Image

Droseefigure3 (Droseefigure3)

Drospirenone Ethinyl Estadiol is a combination of two hormones that are used to prevent pregnancy. Drospirenone is a progestin and ethinyl estradiol is an estrogen. These hormones prevent ovulation (the release of an egg from an ovary) and cause changes in the cervical mucus and the lining of the uterus, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.*

FDA Label Image

Drospeeblistercarton1x28 (Drospeeblistercarton1x28)

Drospirenone and Ethinyl Estradiol Tablets, USP is an oral contraceptive medication that comes in a blister pack containing 28 tablets. Each tablet contains 3mg of drospirenone and 0.02mg of ethinyl estradiol. The medication is manufactured by Cyndoa Prama in Spain and distributed by Gamber Pharmaceuticals in the USA. The package includes 24 pink tablets and 4 white tablets, to be taken in that order for 28 consecutive days per menstrual cycle. It is important to note that this medication does not protect against HIV or other sexually transmitted diseases and is only intended to prevent pregnancy. The recommended storage temperature is between 15°C to 30°C.*

FDA Label Image

Drospeeblistercarton3x28 (Drospeeblistercarton3x28)

This is a description of a medication called Drospirenone and Ethinyl Estradiol Tablets, USP with a dosage of 3 mg/0.02 mg. The package contains three blister cards of 28 tablets each and the medication is manufactured by Cyndea Phama, SL. The recommended dosage is one tablet daily for 28 consecutive days per menstrual cycle, with the tablets taken in a specific order. The medication is intended to prevent pregnancy but does not protect against HIV and other sexually transmitted diseases. The product is available in a pack size of 3 units and is for prescription only.*

FDA Label Image

Drospeecamlogo1 (Drospeecamlogo1)

FDA Label Image

Drospeecamlogo2 (Drospeecamlogo2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.